Frankly, I was among the people who thought five years ago, therell never be small molecules here, because the site youve got to bind is just too big, says Gellman, but he concedes it looks like he was wrong
Originally, they considered that the risk of cardiovascular disease associated with obesity resulted in higher costs than covering these medications for weight loss
however, claims that a specific ingredient helps people taking GLP-1 medications maintain muscle should be made only if supported by evidence for that population and use context
demonstrated the effectiveness and safety of GLP-1 agonists in managing obesity among liver transplant recipients
Whether GLP- 1 increases energy expenditure has also been studied
These numbers are unusually strong for a nonrandomized oncology-adjacent study, which is exactly why they are both intriguing and difficult to accept at face value